Oligonucleotide
Discovery
Our oligonucleotide drug discovery platform is equipped with experienced scientists and state-of-the-art facilities to support your discovery synthesis of oligonucleotides, complex…
Oligonucleotide Discovery Synthesis
Our oligonucleotide drug discovery platform is equipped with experienced scientists and state-of-the-art facilities to support your discovery synthesis of oligonucleotides, complex conjugates, monomers, ligands and linkers, from sequence design to Pre-Clinical Candidiate (PCC).
We provide library synthesis, custom synthesis from nmol to mmol. Our services cover all types of oligonucleotides with dedicated analytical support for all required testing.
We support all types of oligonucleotides, including but not limited to:
- DNA, ASO, PMO
- miRNA, siRNA, sgRNA
- Aptamer
Experience Highlight
- 45,900+ oligonucleotides per year
- 20+ classes of oligonucleotide conjugates
- 55+ PMOs & 45+ PPMOs
- 40+ ribofuranosyl & 10+ backbone modifications
- Expertise in long oligonucleotide synthesis for both ss RNA and ds RNA, with the longest with 158-nt
- Experience with diverse challenging modified oligonucleotide synthesis such as RNA with 3'/5'-GalNAc, lipidation, PEGylation, etc.
Various Synthesizers to Support All Your Needs from nmol – mmol
- nmol – µmol: 192-channel synthesizers
- µmol – mmol: 16 channel synthesizers, OligoPilot 10™ and OligoPilot 100™ synthesizers
Broad Purification Capability
- Cartridge Purification (desalting): High-throughput purification of oligonucleotide library
- Polyacrylamide Gel Electrophoresis (PAGE): Microgram scale purification with rapid delivery
- IP-RP HPLC: Milligram scale purification with endotoxin control
- Anion-Exchange Chromatography (AEX): From gram scale to large scale purification
- Customized Purification Method: Method development by combining IP-RP HPLC and AEX HPLC for high purity requirement
Library Synthesis Experience Highlight
234 siRNA Duplexes (200 nmol each)
144 5’-SMCC Aptamers (375 nmol each)
206 PMOs (300 nmol each)
40+ bp long & high-modified oligonucleotides (10 nmol each)
Case Study: From ‘Library’ Screening to Non-Human Primates Toxicological Development
- Broad Scale: from 1 mg to 10 g
- High Speed: the whole project completed in 10 weeks
- Analytical support at all scales with methods ready for later Tox study
Related Resources
Oligonucleotide CRDMO Chemistry Platform
Oligonucleotide Drug Discovery
Oligonucleotide CRDMO Chemistry Platform
Oligonucleotide Drug Discovery
Why WuXi TIDES
What this platform adds
Scalability
From discovery to commercialisation entirely within WuXi TIDES, with readily available large R&D and manufacturing capacity.
Conjugation Chemistry
Seamless collaboration across the oligonucleotide, peptide and small molecule teams — the conjugates nobody else wants to touch.
New Technology
Biocatalysis for gRNA synthesis, thin film evaporation, reactor-in-series with PAT, continuous flow chromatography, TFF.
Global Quality Standard
One quality system across every site, approved by the major regulatory agencies around the world.
Comprehensive Analytical
Method development and validation, IPC and release testing, characterisation and stability under one roof.
Integrated CMC
API and formulation development, manufacturing, analytical, dossier preparation and clinical supply as a single programme.
Meeting global quality standards
Inspection record
How can we help?
Our TIDES drug experts stand ready.
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA